Publicacions en què col·labora amb MARÍA GÓMEZ CAÑAS (7)

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties

    European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80

2015

  1. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

2014

  1. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 73, pp. 56-72